A Phase II, Multicenter, Single-Arm Study of Oral Ceritinib in Adult Patients With ALK and ROS1 Activated Gastrointestinal Malignancies

What is the purpose of this trial?

The available data indicate that Ceritinib has substantial anti-tumor activity in patients with anaplastic lymphoma kinase (ALK) and ROS1 rearranged non-small cell lung cancer (NSCLC). This trial will investigate the potential of Ceritinib in patients with advanced gastrointestinal malignancies with ALK and ROA1 rearrangement, and for whom there is no available therapeutic option.


Participation Guidelines

Ages: 18 years and older

Gender: Both


Academic GI Cancer Consortium (AGICC)

Dates: 11/30/2016 - 08/31/2017

Last Updated: 12/20/2017

Study HIC#: 1606018017

Get Involved

For more information about this study, contact:
Kamil Sadowski
+1 203-785-6666
kamil.sadowski@yale.edu

If you would prefer to contact a member of the Help us Discover team about this trial and other similar trials, please email helpusdiscover@yale.edu or call 1-877-978-8348.

Trial Image